Merck Outlines Plans For 2009 NDA Filings; Migraine Drug Is Best Bet
Executive Summary
Merck's fledgling bioventures business may have dominated headlines following the company's recent analyst day, but the firm's other initiatives are likely to contribute more to near-term growth as Merck tries to address the revenue gap that will be left by key patent expirations in the next few years
You may also be interested in...
Merck U.S. Restructuring Not To Blame For Q1 Sales Drop, Execs Say
Merck is assuring analysts that its massive commercial restructuring continues to benefit, not stifle, product growth, as company executives reported lower-than-expected sales and earnings April 21
Merck U.S. Restructuring Not To Blame For Q1 Sales Drop, Execs Say
Merck is assuring analysts that its massive commercial restructuring continues to benefit, not stifle, product growth, as company executives reported lower-than-expected sales and earnings April 21
Merck’s Ambitious Plans For Follow-On Biologics
Merck outlined ambitious plans for launching and growing a follow-on biologics business during its annual business briefing Dec. 9